(Q34548522)

English

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

multicenter clinical trial

0 references

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

author name string

S R Lentz

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

S Ehrenforth

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

F Abdul Karim

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

T Matsushita

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

K N Weldingh

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

J Windyga

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

J N Mahlangu

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

adept™2 investigators

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

16 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1244-1253

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Vatreptacog alfa from conception to clinical proof of concept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Factor VII mutant V154G models a zymogen-like form of factor VIIa.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238784

7 July 2018

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12634

21 January 2018

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24931322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/24931322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/JTH.12634

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34548522&oldid=1554584206"